The FDA has approved Selarsdi (ustekinumab-aken) as interchangeable to the reference product Stelara (ustekinumab).

Pronounced “soh-TIK-too,” SOTYKTU is a once-daily pill for adults with moderate to severe plaque psoriasis that works inside ...

The biosimilar SYSA1902 is similar to reference ustekinumab for both efficacy and safety measures among patients with plaque psoriasis.

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi ...

Selarsdi, a biosimilar to Stelara, is approved for adult and pediatric psoriatic arthritis, plaque psoriasis, Crohn disease, ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , and Alvotech today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDItm (ustekinumab-aekn) ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) ...

Ustekinumab binds to the p40 subunit of interleukin (IL)-12 and IL-23 and prevents their interaction with the cell surface IL ...

Joni Kazantzis didn't think her psoriasis would turn into psoriatic arthritis. But the new diagnosis taught her—and her ...